Agile Therapeutics Inc. (NASDAQ:AGRX) currently has a daily average trading volume of 1.25M but it saw 434829 shares traded on Wednesday. With a market cap of 8.22M USD, stock’s current market price of $0.19 came rising about 0.05 while comparing to the previous closing price of $0.19. In past 52 weeks, the stock remained buoying in the range of price level as high as $29.60 and as low as $0.18. In the recent trading on the day, stock has struck highest price mark of $0.2045 while lowest mark touched by it was $0.19.
Taking a look at 20-day trading activity of Agile Therapeutics Inc. (AGRX) gives us an average price of $0.2404, while its current price level is -99.34% below from 52-week high level whereas it is 6.01% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.2724 while that of 200 days or SMA-200 reads an average of $3.1196. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.57% during that period while stretching the period over a month that increases to 11.56%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.95 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the RBC Capital Mkts which resumed the stock as “Outperform” in its note to investors issued on April 07, 2021, recommending a price target of $8 for it. Maxim Group issued its recommendations for the stock as it initiated the price target for the stock is $3.
Over the week, AGRX’s stock price is moving -11.78% down while it is -28.15% when we observe its performance for the past one month. Year-to-date it is -99.01% down and over the past year, the stock is showing a downside performance of -99.16%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$2.71 beat the consensus estimate of -$3.7 for the same. For AGRX, analysts are forecasting an EPS-growth rate of 93.00% for current year and estimate for EPS growth in next year is 71.30%. In next quarter, company is expected to be making quarterly sales of $3.12 million as analysts are expecting the sales for current fiscal year at $9.2 million and seeing the company making $22.24 million in sales next year. Moreover, analysts are in estimates of $2.33 million for current-quarter revenue.
Currently, Agile Therapeutics Inc.’s total number of outstanding shares is 37.00M with 1.57% of that held by the insiders while 0.55% of its common stock has been owned by the institutions. Stock’s beta reads 1.21. Stock has a price to book (P/B) ratio of 1.14 while price to sale or P/S ratio amounts to 0.98. Its return on asset (ROA) is -223.50% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Fidelity Extended Market Index Fu came shrinking its share ownership by 1,892.26% in the Agile Therapeutics Inc. (AGRX) increasing its stake to 0.54% with control over 0.2 million shares in the company. As per SEC documents, Fidelity Extended Market Index Fu sought 209,167 of company’s common stock of worth $58358.0 as per recent closing price of the stock. Fidelity Extended Market Index Fu is not the only institutional holder which restructured its stake in Agile Therapeutics Inc., as Vanguard Extended Market Index Fu picked 75,995 shares of worth $21203.0 to bring its holdings to a total of 46576.0 shares.